



*cancers*



an Open Access Journal by MDPI

## New Insights into Targeted Drugs for Breast Cancer

Guest Editors:

**Dr. Jennifer Diamond**

University of Colorado Cancer  
Center, University of Colorado  
Anschutz Medical Campus, 12801  
E 17th Ave, MS8117, Aurora, CO  
80045, USA

**Dr. Jennifer Richer**

Department of Pathology,  
Anschutz Medical Campus,  
University of Colorado, Aurora,  
CO 80045, USA

Deadline for manuscript  
submissions:

**closed (31 May 2023)**

### Message from the Guest Editors

Over the last decade we have seen a rapid increase in targeted therapies for breast cancer, including in hormone receptor (HR) positive, HER2+ and triple-negative breast cancers (TNBC). The development of CDK4/6, PI3K and new SERDs in HR+ breast cancer, new HER2-targeted therapies (including small molecule inhibitors, ADCs and monoclonal antibodies) and Trop2-ADCs and PARP inhibitors for TNBC and BRCA-mutated cancers, respectively, has changes the way we treat patients with all breast cancer subtypes. These advances have improved patient outcomes and give clinicians more treatment options.

For this Special Issue, we welcome original and review papers focused on targeted therapies in breast cancer, including novel rational combinations and strategies to overcome treatment resistance. While the issue is not focused on immunotherapy, works focused on combination strategies including immunotherapy and targeted therapies are also encouraged.



[mdpi.com/si/95187](https://mdpi.com/si/95187)

# Special Issue



# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI